In Silico Evaluation of Tangeretine as Potential Target for Breast Cancer Gene 1 Implicated in Prostate Cancer Disease.

View Full Paper

Ask AI

Bookmark

Tangeretin shows a binding affinity of -5.552 kcal/mol with BRCA1, indicating potential therapeutic effects.
The compound complies with Lipinski's rule, indicating good bioavailability and possible efficacy in cancer treatment.
In silico evaluation reveals tangeretin's molecular weight at 372.37 g/mol and a bioavailability score of 0.55.
The study suggests that tangeretin may serve as a natural therapeutic option for prostate cancer patients unable to afford existing treatments.

Discussion

No takes yet. Share an insight, caveat, or question.

In silico analysis shows tangeretin's affinity for BRCA1 in prostate cancer, suggesting natural therapy potential.

Oyewole et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark